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Abstract 
Haemoglobin is the blood’s oxygen carrying pigment and is encapsulated in red blood corpuscles. The concentration 
of haemoglobin in blood is dependent on both its total mass in the circulation (tHb-mass) and the total plasma vol-
ume in which it is suspended. Aerobic capacity is defined as the maximum amount of oxygen that can be consumed 
by the body per unit time and is one measure of physical fitness. Observations in athletes who have undergone blood 
doping or manipulation have revealed a closer relationship between physical fitness (aerobic capacity) and total 
haemoglobin mass (tHb-mass) than with haemoglobin concentration ([Hb]). Anaemia is defined by the World Health 
Organisation (WHO) as a haemoglobin concentration of <130 g/L for men and <120 g/L for women. Perioperative 
anaemia is a common problem and is associated with increased mortality and morbidity following surgery. Aerobic 
capacity is also associated with outcome following major surgery, with less fit patients having a higher incidence 
of mortality and morbidity after surgery. Taken together, these observations suggest that targeted preoperative 
elevation of tHb-mass may raise aerobic capacity both directly and indirectly (by augmenting preoperative exercise 
initiatives- ‘prehabilitation’) and thus improve postoperative outcome. This notion in turn raises a number of ques-
tions. Which measure ([Hb] or tHb-mass) has the most value for the description of oxygen carrying capacity? Which 
measure has the most utility for targeting therapies to manipulate haemoglobin levels? Do the newer agents being 
used for blood manipulation (to increase tHb-mass) in elite sport have utility in the clinical environment? This review 
explores the literature relating to blood manipulation in elite sport as well as the relationship between perioperative 
anaemia, physical fitness and outcome following surgery, and suggests some avenues for exploring this area further.
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Background
Haemoglobin is the blood’s oxygen carrying pigment. 
Erythropoietin is the hormone that stimulates human 
haemoglobin (and red blood corpuscle) synthesis. Its 
synthetic recombinant form (rHuEPO) is commonly 
used in clinical practice to augment haemoglobin levels, 
as is the use of agents that support haemoglobin synthe-
sis (such as intravenous or oral iron, vitamin B12 or folic 
acid) when these are deficient. Hypoxia-inducible factor 
(HIF) is a transcriptional regulator that (amongst other 
effects) drives erythropoietin synthesis, and whereby 
enhances haemoglobin levels. The first recorded human 
blood transfusion took place in 1795 [1] and homolo-
gous blood transfusion is widely used in clinical practice 
for anaemic patients, including during the perioperative 
period. Some elite athletes have illegally tried to enhance 
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their performance by increasing their haemoglobin lev-
els and thereby increasing their oxygen carrying capacity 
via the so-called ‘blood doping’. Such activities have often 
taken place prior to rigorous safety trials (being properly 
performed for medical benefit) that are a measure of the 
risks that such athletes are prepared to take to achieve 
success [2]. For example, there is evidence that the new 
HIF activators are being abused within elite sport [3–6].
Aerobic capacity is defined as the maximum amount of 
oxygen that can be consumed by the body per unit time 
and is one measure of the physical fitness. V˙O2max is clas-
sically defined as ‘a plateau in oxygen uptake attained 
during maximal exercise despite further increases in 
exercise workload, thereby defining the limits of the car-
diorespiratory system’ [7]. However, many individuals do 
not reach a plateau in oxygen uptake despite maximum 
exertion, and the term V˙O2peak is used instead, being the 
highest measured oxygen consumption during exercise, 
typically averaged over a 30  s period. V˙O2 at anaerobic 
threshold is defined as ‘the highest sustained intensity of 
exercise for which the measurement of oxygen uptake can 
account for the entire energy requirement’. An alternative 
definition is ‘the exercise intensity at which lactate starts 
to accumulate in the blood stream’ [8]. These oxygen 
uptake variables are in part dependent on the oxygen car-
rying capacity of the blood, which is in turn dependent 
on blood haemoglobin levels.
Anaemia is defined by the World Health Organisation 
(WHO) as a haemoglobin concentration of <130 g/L for 
men and <120 g/L for women [9]. Perioperative anaemia 
is common, with a quoted prevalence varying between 
16 and 47  % reported in different patient cohorts (see 
Table 1), and is associated with increased morbidity and 
mortality following surgery. Using data from the Euro-
pean Surgical Outcomes Study (EuSOS) [10], Baron et al 
found that the presence of moderate anaemia was associ-
ated with a higher likelihood of in-hospital mortality than 
when it was absent, after adjustment for co-morbidities 
and the severity of the surgery [odds ratio (OR) 1.99–
95  %; confidence intervals (CI) 1.67–2.37] [11]. Both V˙
O2peak and V˙O2AT are positively correlated with outcome 
following major surgery: less physically fit patients hav-
ing a higher incidence of mortality and morbidity after 
surgery. Much of the literature in this area is derived 
from studies reporting cardiopulmonary exercise test-
ing (CPET) variables. The underlying hypothesis of these 
studies has been that patients with greater physiologi-
cal reserve defined by CPET variables (most commonly 
V˙O2peak and V˙O2AT) are better able to withstand the 
physiological challenge of surgery. Given that the oxygen 
uptake variables V˙O2peak and V˙O2AT are correlated with 
[Hb], it may be that some of the physical fitness–outcome 
relationship is mediated through haemoglobin related 
effects rather than cardiorespiratory function.
Prehabilitation is the process of enhancing func-
tional capacity of the individual to enable him or her to 
withstand a subsequent stressor. This may be achieved 
through a single well-defined intervention (e.g. struc-
tured aerobic exercise programme) [20] or may encom-
pass a package of smaller integrated steps leading to 
overall functional improvement, the so-called ‘aggre-
gation of marginal gains’ [21–23]. Such interventions 
have a role in prehabilitation within clinical medicine 
in general, and before major surgery in particular. How-
ever, whilst the efficacy of such approaches in improv-
ing physical fitness is becoming clearer [20, 24], it is 
currently uncertain whether they will be effective in 
improving clinical outcomes in the perioperative set-
ting. As we learn more about the relationship between 
physical fitness, defined by CPET-derived variables, and 
responses to prehabilitation in different patient groups, 
it may be that lessons learned from elite athletes could 
be applied to improving outcomes in patients around the 
time of surgery.
Table 1 Prevalence of preoperative anaemia
Broadly based on WHO definition of anaemia, <130 g/L for men and <120 g/L for non-pregnant women
Study Cohort Study population Prevalence of anaemia (%)
Baron—BMJ 2014 [11] Non-cardiac, non-neurological surgery 46,539 28.7
Sagger—Anesth Analg 2013 [12] Non-cardiac surgery 574,860 25.3
Gupta Ann Surgery 2013 [13] Patients over 65 elective vascular surgery 31,857 47
Musallam Lancet 2011 [14] Non-cardiac surgery 227,425 30.44
Van Straten—Circulation 2009 [15] Cardiac surgery 10,025 16
Beattie—Anaesthesiology 2009 [16] Non-cardiac surgery 7759 39.5
Karkouti—Circulation 2008 [17] Cardiac surgery 3500 26
Kulier—Circulation 2007 [18] Cardiac surgery 4804 28.1 male
35.9 female
Wu JAMA 2007 [19] Non-cardiac surgery 310,311 42.8
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Measuring haemoglobin concentration vs. total 
haemoglobin mass
Traditionally, the concentration of circulating haemoglo-
bin [Hb] has been used as a clinical measure of the blood’s 
oxygen carrying capacity. However, a low [Hb] may be 
due to a reduced amount of haemoglobin (absolute mass 
of circulating haemoglobin; tHb-mass) or an increased 
volume of dilution (plasma volume). Thus, [Hb] may be 
stable and tHb-mass low in the context of acute bleeding, 
[Hb] normal or elevated but tHb-mass low in the context 
of dehydration, or [Hb] low but tHb-mass normal or high 
in the context of excess plasma volume (fluid). Therefore, 
the use of [Hb] to define blood oxygen carrying capacity 
may be misleading under some circumstances.
tHb-mass represents the absolute mass of circulat-
ing haemoglobin in the body, the measured [Hb] being 
dependent upon tHb-mass and blood volume (BV) 
[sum of plasma volume (PV) and total red cell vol-
ume]. The proportion of oxygen carried in solution in 
plasma is trivial (0.3  ml per 100  ml of plasma) under 
normal physiological conditions, whereas each gram 
of Hb binds up to 1.39  ml of oxygen. Thus, tHb-mass 
is the principal determinant of total blood O2-carry-
ing capacity and may provide additional information 
regarding the clinical status of patients than that pro-
vided by [Hb] alone.
It appears that tHb-mass is of greater utility in blood 
manipulation in elite athletes trying to improve sporting 
performance as it is more stable and predictable over time 
and also has a more direct correlation with performance. 
The question addressed by this review is whether tHb-
mass, in comparison with haemoglobin concentration, 
is a more precise and accurate variable to guide target-
ing of haemoglobin manipulation, if the aim is to improve 
physiological reserve in patients in order to improve clini-
cal outcomes. We also explore the techniques of blood 
manipulation in elite athletes and whether any of these 
techniques may be useful from a prehabilitation perspec-
tive within clinical medicine.
Haemoglobin manipulation in sport
Athletes and coaches are constantly pursuing legal 
means, such as training at altitude to augment oxygen 
carriage through an increase in [Hb] and thereby improv-
ing sea-level performance. However, recent revelations 
relating to high profile individuals within professional 
cycling, including Floyd Landis, Tyler Hamilton [25] 
and Lance Armstrong [26], have highlighted the illegal 
methods used by some athletes to improve performance, 
often in advance of the efforts of regulatory authorities to 
constrain them and of their adoption into clinical medi-
cine [27]. It is legitimate to question whether such meth-
ods are safe (or at least fall within the broad margins of 
safety), if they are effective and if they could have wider 
applicability within clinical medicine.
Whilst a variety of agents have been used to manipu-
late haemoglobin levels (e.g. blood, recombinant human 
erythropoietin (rHuEPO), Continuous Erythropoietin 
Receptor Activator (CERA), hypoxia-inducible factor 
(HIFs) agents and possibly even ‘gene doping’ (although 
we do not yet have definitive evidence of this [28, 29]), 
the basic aim remains the same that increasing oxygen 
delivery (DO2) through elevating haemoglobin levels will 
augment maximum oxygen uptake (V˙O2max) and perhaps 
more importantly (for endurance events) increase the 
workload at which anaerobic threshold (AT) is reached. 
There is still debate around the factors that limit V˙O2max, 
with candidate mechanisms including central control, 
cardiac limitation, mitochondrial utilisation and total 
oxygen delivery (the product of cardiac output and 
blood oxygen content). However, whilst there remains 
uncertainty about the dominant controlling factor, many 
authorities agree that in highly trained athletes, DO2 is 
a factor that contributes to V˙O2max limitation [30–32] 
and that V˙O2max is also, at least in part, dependent on a 
number of underlying genetic factors that are not amend-
able to modification through training [33]. Therefore, 
blood manipulation to augment DO2 has been seen as a 
logical, albeit illegal, approach to augmenting V˙O2max and 
thereby improving athletic performance. It is notable in 
this regard that tHb-mass displays a much stronger rela-
tionship with V˙O2max than does [Hb] [34, 35] and may 
therefore be a more useful marker of intervention effi-
cacy. Here, the relationship between different physiologi-
cal measures of physical fitness and performance merits 
consideration. Whilst the majority of sports research has 
focused on V˙O2peak or V˙O2max as the accepted gold stand-
ard indices of cardiorespiratory fitness, other variables 
may have an important role in determining performance, 
particularly in endurance events. As exercise increases 
above a threshold submaximal work rate, anaerobic res-
piration begins to contribute to Adenosine Triphosphate 
(ATP) production and this is both inefficient (relative to 
aerobic respiration) and unsustainable (due to progres-
sive lactic acidosis). Therefore, when discussing perfor-
mance, although a high total aerobic capacity (V˙O2peak/ V˙
O2max) is important for success in endurance sports, sub-
maximal indices of fitness, such as the lactate or anaero-
bic threshold (LT/AT) and exercise efficiency/economy, 
may also be critical determinants of performance. For 
example, two athletes with the same V˙O2max do not nec-
essarily perform to the same level in an endurance per-
formance test or race: the athlete with the higher V˙O2AT 
is likely to perform better. Furthermore, the efficiency 
or economy with which work is done relative to energy 
expenditure may be important. For example, Lucia et al 
Page 4 of 11Plumb et al. Extrem Physiol Med  (2016) 5:5 
showed that a range of V˙O2max levels amongst elite 
cyclists could be compensated for by differences in effi-
ciency [36]. Whilst improvements to V˙O2max are impor-
tant, very few athletic competitions are performed at V˙
O2max and it cannot therefore be assumed that perfor-
mance will be enhanced to the same degree as V˙O2max 
increases. Intriguingly, the premise that improvement in 
physiological variables (i.e. aerobic capacity) enhances 
athletic performance (i.e. races or gold medals won) has 
not been well investigated. Having said that, the effects of 
blood manipulation on a range of physiological variables, 
including to V˙O2max/peak and V˙O2AT, are both of relevance 
for athletes and may have significance in clinical contexts 
[37].
What is ‘blood manipulation’/‘blood doping’?
The World Anti-Doping Agency (WADA) defines blood 
manipulation as the reintroduction of blood or blood 
products allogenic (homologous) or heterologous, the 
artificial enhancement of oxygen transportation or deliv-
ery and any form of intravascular manipulation of the 
blood or its components by physical or chemical means 
[3]. Blood doping is complex and rapidly evolving, as 
highlighted by the recent WADA amendments to the 
2014 prohibited list consequent on the emergent use of 
Xenon and Argon as HIF activators. It was reported that 
Russian athletes used HIF activators at the 2014 winter 
Olympics in Sochi [3]. The earliest reports of ‘blood dop-
ing’ in the scientific literature date back to 1945–1947 
[38, 39]. The first alleged use in elite sport was in the 
1960s, when a French four times Tour de France win-
ner (1961–1964) was named as one of the first cyclists to 
use the technique [40]. The first reported use in athlet-
ics comes from around the time of the 1968 Mexico City 
Olympic Games.
It has been said, “Increasing the oxygen transport 
capacity of the exercising skeletal muscles, either by 
means of training or doping, is the most powerful tool for 
improving athletic performance in aerobic sports [41]”. 
Below we will briefly outline some of the methods of 
blood manipulation used in sport.
Autologous blood transfusion
The link between the O2-carrying capacity of the blood 
and indices of exercise capacity such as V˙O2max has 
recently been reviewed elsewhere [34]. Haematocrit 
(Hct) is also known as packed cell volume (PCV) or 
erythrocyte volume (ECV) and is the volume percentage 
of red blood cells within the blood. There does not appear 
to be a simple linear correlation between haematocrit 
and increased V˙O2max. Brun et  al showed that a “low” 
haematocrit (Hct) (<40 %) was associated with a higher 
aerobic capacity [42]. However, this must be interpreted 
with caution, as the lowest Hct was only 36.8  % (i.e. 
not actually that low). It is probable that lower Hct lev-
els, such as those seen in patients rather than athletes 
or healthy volunteers, would result in a reduced oxygen 
carrying capacity and therefore reduced V˙O2max. By the 
1970s, it was becoming well known that increasing tHb-
mass could increase V˙O2max. It later became clear that 
other factors were also important, for example, changes 
in diastolic function and changes in blood volume (BV) 
[43].
A 1982 review documented all published studies com-
paring exercise testing variables pre-phlebotomy, and 
post transfusion, at that time. It is apparent from Table 2 
that a significant increase in [Hb] was associated with an 
increase in V˙O2max. The author concluded that at least 
2 units of blood were needed with frozen blood being 
superior to refrigerated blood [44]. Of the 14 studies in 
Table  2, only 5 of them showed statistically significant 
improvements in [Hb] and V˙O2max post autologous trans-
fusion [39, 45–48]. The results of studies failing to find 
such a relationship between [Hb] and exercise capacity 
may in part be explained by the small quantity of blood 
re-infused, insufficient time for the body to achieve equi-
librium [Hb] after venesection, and inadequate storage of 
the RBCs [44].
In general, autologous blood transfusion seems to 
improve performance, but there are very few studies 
addressing this question directly. Improved 5-mile tread-
mill run times (mean improvement of 44 s) with reduced 
self-reported perceived exertion after autologous blood 
transfusion were demonstrated by Williams et  al [47]. 
Berglund et al demonstrated a significant fall in the race 
times of cross-country skiers when compared to matched 
controls pre- and post autologous blood transfusion [49]. 
Brien et  al took 6 well-trained runners and improved 
their 10 km time by an average of 1 min. Using a double-
blind cross-over design, each runner received a 400  ml 
autologous transfusion of blood or saline repeated again 
5  days apart with a 10  km race 5  days after each treat-
ment. Five out of the 6 runners had faster race times after 
transfusion [50].
Recombinant human erythropoietin: rHuEPO
There are more data available for rHuEPO and a num-
ber of studies have shown correlation between improved 
performance and rHuEPO use. In 1991, Ekblom et  al 
showed an improved V˙O2max post rHuEPO injection in 
15 volunteers [51]. Similar results were shown by Audran 
et al. Table 2 from this paper shows the increase in Hct 
and [Hb] from day 0 to day 24 and subsequent rise in V˙
O2max with reduction in maximum heart rate [52]. Pari-
sotto et al attempted to develop a blood profile to detect 
athletes who were abusing rHuEPO and were able to 
Page 5 of 11Plumb et al. Extrem Physiol Med  (2016) 5:5 
demonstrate a predictable blood profile post rHuEPO 
usage. They measured tHb-mass (using Burge and Skin-
ner’s method) and found a consistent increase in Hct, 
[Hb] and tHb-mass 3  weeks after rHuEPO adminis-
tration, which persisted for 21  days. They also found a 
6.3 and 6.9  % increase in V˙O2max compared to placebo. 
After a 4-week washout period, tHb-mass and V˙O2max 
had returned to baseline [53]. Birkeland et al showed in 
a double-blind placebo-controlled trial that injection of 
5000 IU of rHuEPO thrice weekly for 4 weeks improved 
V˙O2max by 7 %. They found that Hct rose from a mean of 
42.7–50.8 and peaked 1 day after rHuEPO was stopped. 
Haemoglobin concentration also increased in the 
rHuEPO group [54].
However, data supporting an improvement in per-
formance following rHuEPO usage in athletes were still 
limited. Russell et al were the first to characterise the sub-
maximal and maximal exercise adaptations to prolonged 
use of low dose rHuEPO. They compared 3 groups, (1) 
intravenous (i.v.) iron + rHuEPO, (2) oral iron + rHuEPO 
and (3) placebo. They performed exercise tests on a cycle 
ergometer at weeks 0, 4, 8 and 12. The relative increases 
in V˙O2max at weeks 4, 8 and 12 were 7.7, 9.7 and 4.5 %, 
respectively, for the rHuEPO  +  i.v. iron group; 6.0, 4.7 
and 3.1 % for the oral iron +  rHuEPO group; and −0.5, 
−0.1 and −1.0 % for the placebo group [55].
In 2007, Thomsen et al stated that “Although the posi-
tive effect of rHuEPO treatment on V˙O2max is clearly 
established, it remains unknown as to what its impact is 
on endurance performance”. They investigated the effect 
of rHuEPO on V˙O2max and time to exhaustion during 
cycle ergometry in healthy volunteers. rHuEPO signifi-
cantly increased V˙O2max by 9.1 and 8.1 % in week 4 and 
11, respectively, with no changes in the placebo group 
[37].
Emerging strategies
The range of interventions aimed at increasing tHb-mass, 
both in development and currently available, is large and 
has been extensively reviewed elsewhere [2, 4, 6, 56].
Towards the end of the 1990s, interest had grown 
within clinical medicine and the sporting world in using 
Table 2 Summary of studies of blood doping and exercise
Reproduced with permission from Wolters Kluwer Health [44]
NR data not reported, Refridg refrigerated
a Whole blood or equivalent whole blood
b Control pre-phlebotomy measurement
c Endurance exercise capacity, physical work capacity or performance time
d Statistically significant (P ≤ 0.05)
e No statistical analysis reported
f Predicted from submaximal exercise heart rate
g Fresh homologous blood; all other studies used autologous blood
Authors Date Storage tech-
nique
Volume infuseda 
(ml)
Time of reinfusion 
post phlebotomy
Hb or Hct vs con-
trolb (%)
V˙O2max vs control 
(%)
End capacityc vs 
controlb (%)
Pace et al 1947 Freshg 2000 – +26d N.R +34.7d
Gullbring et al 1960 Refridg 610 7 days +0.7 N.R +3
Robinson et al 1966 Refridg 1000 2 weeks +4.8 +1.4 N.R
Ekblom et al 1972 Refridg 800 4 weeks +2.1 +5.5e + 15.6e
Refridg 1200 4 weeks +1.3 +1.6e + 25.1e
Von Rost et al 1975 Refridg 900 3 weeks +2.7 +9.0e + 375
Bell et al 1976 Refridg 500 3 weeks +1.0 +5.6f + 7.5
Ekblom et al 1976 Refridg 800 ~5 weeks +4.5e +8.0d N.R
Videman and 
RytÖmaa
1977 Refridg 4–600 2–3 weeks +2.6 N.R + 3.8
Robertson et al 1978 Abst N.R 1800 NR N.R. +12.8d + 15.6d
Williams et al 1978 Frozen 460 3 weeks +3.3 N.R + 4.1
Cottrell 1979 Abst Frozen 405 9 weeks N.R. ~+2.0f N.R
Roberston et al 1979 Abst N.R 800 N.R. +15.8d +30.5d + 13.1d
Buick et al 1980 Frozen 900 7 weeks +11d +5d + 35d
Spriet et al 1980 Abst Frozen 800 11 weeks +7.9d +3.9d N.R
1200 12 weeks +10.7d +6.6d N.R
Williams et al 1981 Frozen 920 7 weeks +7d N.R +2.5d
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artificial oxygen carriers and perfluorocarbon emulsions 
[57]. However, neither has been adopted in either setting, 
probably due to well-recognised adverse effects and ease 
of detection [58].
HIF stabilisers/activators are compounds that act by 
mimicking hypoxia and thereby stimulating EPO syn-
thesis via the HIF pathway. When the partial pressure of 
oxygen is low, HIF1α undergoes a stabilisation process, 
which leads to gene transcription, including that of the 
erythropoietin gene [59, 60]. HIF stabilisers/activators 
are oral compounds, which are potentially advantageous 
as they are simply administered and are less immu-
nogenic than erythrocyte-stimulating agents such as 
rHuEPO. The number of agents available is beyond the 
scope of this review and has recently been summarised 
elsewhere [2]. There is already clear evidence of their 
abuse within elite sport [3–5, 56]. Cobalt is one such 
agent, which has adverse effects including heart, liver, 
kidney and thyroid toxicity as well as cancer promotion 
[61]. There is evidence of cobalt being abused in horse 
racing [62]. Xenon and argon are also both HIF activa-
tors and have both been reportedly used as performance-
enhancing agents in the recent years [3, 63].
Gene therapy is also theoretically possible, but some 
early reports highlighting significant safety concerns 
including life-threatening red cell aplasia and extreme 
erythrocytosis have probably limited its use [64]. There 
are also EPO-mimetic peptides such as Peginesatide that 
are not currently in production but are nevertheless can-
didates for abuse [2].
Harms: what are the downsides?
Not only is blood manipulation/doping illegal, but also 
many of the agents used may pose health risks to the ath-
lete. Despite this, some athletes are apparently prepared 
to accept such risks to increase their chances of success. 
As has already been noted, manipulation of haemoglobin 
may be associated with a variety of adverse effects includ-
ing, for example, hyper-viscosity from rHuEPO and the 
toxic effect of cobalt. The risks associated with blood 
transfusion are summarised in Table 3.
Haemoglobin manipulation in the clinical setting
Blood manipulation occurs commonly in clinical prac-
tice. In the UK, approximately 8000 units of blood are 
transfused each day [69] including homologous trans-
fusion and transfusion of blood salvaged during major 
surgery. The level of anaemia that mandates blood trans-
fusion is not well defined in all perioperative settings 
[67, 70–74] and there has been a shift over the last two 
decades towards more conservative transfusion strate-
gies, particularly within intensive care [75, 76]. Whilst 
the association of anaemia with adverse outcome is well 
recognised, uncertainty remains as to whether this rela-
tionship is causal and about when and how to intervene 
in the perioperative period. It is unclear whether anaemia 
per se causes increased morbidity/mortality or whether 
anaemia is associated with other (perhaps unidentified) 
pathology, which is the cause of the adverse outcomes. 
Whilst the study by Baron et  al suggests that anaemia 
alone (once all co-morbidities are corrected for) is associ-
ated with an increased mortality in perioperative patients 
[11], residual confounding cannot be excluded due to the 
observational design of this study. Of note, measures to 
correct anaemia (including transfusion) seem ineffec-
tive at reducing the incidence of adverse outcome. This 
may be because anaemia is not the cause of the under-
lying pathology, in which case correcting anaemia would 
not be expected to improve outcome, or alternatively that 
adverse consequences of the interventions used (such 
as blood transfusion) outweigh the benefits of correct-
ing anaemia. It is commonly hypothesised that much 
of the morbidity associated with a more liberal transfu-
sion strategy is due to the adverse effects of homologous 
stored blood rather than the increased oxygen carrying 
capacity actually being ineffective. The on-going evolu-
tion of preparation techniques for transfused blood is 
likely continuing to alter the risk–benefit ratio for differ-
ent transfusion strategies. Amongst the multiple reasons 
for potential harm from transfused blood (see Table  3), 
age of the blood is an area that has recently been investi-
gated [77]; however, no significant differences were found 
with regard to 90-day mortality between a fresh blood 
Table 3 Risks associated with  blood transfusion 
and manipulation
Theoretical Demonstrated
Age of stored blood 
may affect its efficacy; 
the so-called ‘storage 
lesion’ [65]
Transfer of infectious diseases [40]
Transfusion reactions/anaphylaxis
Increase in colorectal cancer recurrence [66]
Phlebitis [40]
Septicaemia [40]
Graft versus host disease (GvHD)
Transfusion-related immunomodulation (TRIM) 
[67, 68]
Hyper-viscosity PE and DVT [40]
Air embolism [40]
Transfusion-related acute lung injury (TRALI)
Risk of wrong blood (storage problems) [25]
Detraining effect [40]
Illegal practice to blood dope [25, 26]
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group (6.1 ±  4.9 days) and when compared with stand-
ard blood (22.0 ± 8.4 days) [77]. A recent analysis of the 
FOCUS study comparing a liberal and restrictive strat-
egy in hip fracture patients found no difference in 3-year 
mortality [70]. The balance between the theoretical ben-
efits of augmenting DO2 and the harms of transfusion 
remains unclear: “Blood transfusion is like a marriage: It 
should not be entered into lightly, unadvisedly, or wan-
tonly, or more often than is absolutely necessary” [78].
Two large observational datasets in non-cardiac sur-
gery have shown that anaemic patients spend more 
time in intensive care, suffer more complications, stay in 
hospital longer, consume greater hospital resource and 
are more likely to die [11, 14]. The same pattern is also 
reflected in data from cardiac surgical practice [17, 79]. 
NHS England has issued guidance on the management of 
patients who present for elective surgery. The poor out-
come associated with anaemia has led to the recommen-
dation that these patients have their surgery delayed until 
treatment of their anaemia has occurred [80].
Whilst anaemia is clearly important, some authors have 
questioned its reliability as an independent marker of ill 
health as it may often be linked to an underlying acute 
or chronic disease that may yet be undiagnosed. Inter-
estingly, Baron et  al accounted for this: after adjusting 
for co-morbidities and severity of the surgery, patients 
with moderate anaemia had a higher in-hospital mortal-
ity [odds ratio 1.99 (95 % confidence interval 1.67–2.37)] 
[11]. Despite this, there is currently no convincing evi-
dence that treating the absolute value of [Hb] improves 
outcome.
Importantly, the majority of studies in periopera-
tive transfusion have examined the ‘very anaemic’ and 
attempted to move them to the ‘slightly less anaemic’. Lit-
tle work has been done to manipulate ‘normal physiology’ 
to target supra-optimal DO2 values (through Hb augmen-
tation) in this population. Manipulation of tHb-mass, in 
contrast to [Hb], in patients who are about to undergo a 
physiological challenge, may improve their resilience to 
such an insult. Equating ‘performance’ gains by elite ath-
letes to the ability of patients to survive surgery involves 
a substantial conceptual leap, but recent preliminary 
work has shown that transfusion can improve exercise 
variables in anaemic patients [81]. It remains uncertain 
whether clinical outcomes will alter alongside changes in 
tHb-mass and whether the closer relationship between 
tHb-mass (compared with [Hb]) and performance in the 
athletic context, will be mirrored for patient outcomes 
in the clinical context. Indeed it may be that the meta-
bolic cost of modern surgery has been overestimated, 
thus allowing for an adequate DO2 at ‘low’ O2 carrying 
states. The recent POM-O study was a randomised con-
trolled trial of patients undergoing major elective surgery. 
Patients were randomised to a postoperative protocol 
(fluid, with and without dobutamine) targeted to achieve 
their individual preoperative oxygen delivery value 
(goal-directed therapy) or standardised care (control). 
Maintaining DO2 appeared to be the important factor 
regardless of whether patients were in the goal-directed 
therapy group (fluids and dobutamine) or the usual care 
group [82].
Prehabilitation
Interest in prehabilitation has grown off the back of the 
success of enhanced recovery programmes (ERPs). ERPs 
were set up to try improving surgical outcomes by imple-
menting care pathways. These pathways did not focus on 
discovering new knowledge but placed importance on 
integrating the best evidence into practice. It has been 
shown that exercise testing in patients before surgery is 
feasible and that physiological gains can be made in only 
short periods of time [12, 83, 84], although the clinical 
benefits remain uncertain [24]. CPET may play a role in 
guiding prehabilitation [85].
In a recent study, AT improved by a mean differ-
ence of 1.2 ml kg−1 min−1 in anaemic patients who had 
CPET pre- and post the transfusion of autologous blood 
[81]. The clinical effects of an increase in V˙O2 at the AT 
of around 1 ml kg−1 min−1 are uncertain and this was a 
small single-centre study (with consequent elevated risk 
of bias). However, the results were consistent with a study 
in thalassemic patients, showing improved exercise dura-
tion and V˙O2peak [86]. Pilot et al showed that autologous 
transfusion following hip arthroplasty improved early 
postoperative exercise testing variables, but this effect 
was equivocal by day 23. However, this study was not 
randomised and is therefore subject to risk of both con-
founding and bias [87]. This area needs further research. 
There is an on-going study looking at intravenous iron 
infusion in major abdominal surgery [88]. The transfu-
sion trigger in major elective surgery remains unknown, 
particularly with regard to outcomes such as ability to 
mobilise postoperatively [89]. Within the hip fracture 
population, postoperative anaemia is associated with 
increased length of stay, reduced ambulation and reduced 
functional independence [90]. However, evidence is lack-
ing for a liberal transfusion strategy in non-cardiac sur-
gery ([Hb] 80–100  g/L) and this is consistent with the 
literature in critically unwell patients with septic shock 
[75].
The effects of prehabilitation training on the mito-
chondrial architecture, redox state and muscle capil-
lary network remain unstudied in surgical patients and 
the additional effect of augmenting tHb-mass is also 
unknown. Training effects are of course different from 
the effects of blood manipulation and optimising the 
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most critical steps in mitochondrial oxygen transport by 
training may be superior to using rHuEPO to enhance 
gene expression and induce angiogenesis; however, this 
remains to be elucidated. Exercise modifies mitochon-
drial biogenesis, not only by upregulating antioxidant 
enzymes but also by increasing mitochondrial number, 
thereby allowing for a lower level of respiratory activity 
for the same degree of ATP generation [91, 92]. Interest-
ingly, Jacobs et  al found that improvement in exercise 
performance after six sessions of high intensity training 
(HIT) over the span of 2 weeks was primarily attributed 
to enhanced oxidative potential in the skeletal muscle 
with no measurable effect on tHb-mass [91].
It may be that for some patients DO2 may be critical to 
VO2 and survival, whereas in another group of patients, 
anaemia, fitness levels and DO2 are part of a broader pat-
tern of resilience. The biological pathways whereby regu-
lar physical activity might confer resilience include: (1) 
serving as a buffer against stress and stress-related dis-
orders/chronic diseases, (2) optimising neuroendocrine 
and physiological responses to physical and psychosocial 
stressors, (3) promoting an anti-inflammatory state and 
(4) enhancing neuroplasticity and growth factor expres-
sion [93].
Are we then aiming for the total package of broader 
gains from ‘fitness’ or can we just look at specific targets 
such as tHb-mass? Whilst the complex biological mecha-
nisms that relate ‘fitness’ to resilience remain opaque, it 
could be postulated that differences or gains (from tar-
geted therapy or intervention) seen by patients on the 
CPET bike are simply a result of the other unmeasured 
markers of physical fitness. In the 1990s–2000s, when 
professional cycling had a widespread doping problem, 
highly trained elite athletes were experiencing significant 
gains over and above the increased gains in fitness from 
simply having a greater DO2 (primarily from doping, giv-
ing them a far greater tHb-mass). It is likely that patients 
would benefit from increased fitness levels and pilot data 
suggest that physical training does indeed return fitness 
levels back to baseline after a physiological insult such as 
chemotherapy [20]. Whether increasing tHb-mass offers 
benefit to all patients, or only those in whom it is initially 
subnormal remains to be elucidated.
Future directions
We know that the manipulation of tHb-mass is possible 
via a number of strategies. There is good evidence that 
CPET variables can be improved in line with gains in 
tHb-mass in athletes. We also know that fitness relates 
to outcome following surgery. What is not known is if 
the same relationship between physical fitness (CPET 
variables) and tHb-mass exists in patients who are 
awaiting major surgery or critically ill in hospital. The 
measurement of tHb-mass and correlation to CPET var-
iables has not been studied within clinical medicine. It is 
also not clear which method would be best to manipu-
late tHb-mass in patients and what would represent the 
‘optimal’ tHb-mass in each individual, balancing the 
risks of an increased tHb-mass with the theoretical ben-
efits of improved oxygen delivery. We hypothesise that 
tHb-mass is a more accurate variable to guide and quan-
tify potential intervention than [Hb] as it is relatively 
more stable [94–97] and is not affected by changes in 
plasma volume which may vary greatly in the periopera-
tive period.
Informative studies might focus on measuring tHb-
mass in different patient groups and quantifying the rela-
tionship with CPET variables. Initial work to establish 
safety margins for different levels of haemoglobin mass 
in the perioperative period and the safest method for 
achieving them would be valuable. Preliminary studies to 
establish the strength of relationship between tHb-mass 
and outcome in comparison with that of [Hb] would also 
be of value. It may then be justifiable to explore whether 
manipulation of tHb-mass, rather than [Hb], has a posi-
tive effect on surgical outcomes in adequately powered 
randomised controlled trials.
It is not known what an increased tHb-mass does to 
mitochondrial function or if the benefits of training 
that come from a high intensity programme, in terms 
of improved mitochondrial content and function [91], 
can be augmented by boosting tHb-mass via rHuEPO, 
autologous blood transfusion or iron therapy. The ergo-
genic effects of EPO independent of its effect on boosting 
tHb-mass warrant further study and it is likely that there 
is a complex interplay between erythropoietin concentra-
tions, reticulocyte migration and gene expression that 
may affect CPET variables and possibly outcome.
Conclusions
In performance sport, blood doping continues to be a 
problem. Novel agents are continually being developed 
and the regulatory bodies struggle to catch up with the 
dopers. The success of such strategies raises the question 
as to whether some of these approaches may have utility 
in clinical practice.
In particular, the closer relationship between tHb-mass 
(rather than [Hb]) and V˙O2max raises the question as to 
whether we should be targeting this variable with blood 
manipulation techniques in the clinical setting.
The recognised association between low levels of physi-
cal fitness and adverse clinical outcomes in the periop-
erative context offer a specific clinical setting in which it 
may be valuable to address these questions. Furthermore, 
preoperative exercise training interventions (prehabilita-
tion) may be optimised by such an approach.
Page 9 of 11Plumb et al. Extrem Physiol Med  (2016) 5:5 
Observational studies clarifying the relationship 
between tHb-mass and physical fitness and clinical out-
comes in patients are required before interventional 
studies using this variable to target blood manipulation 
strategies are justified. The newer agents being used for 
blood manipulation in elite sport may have utility in this 
respect in the clinical environment.
Health warning
Blood doping/boosting or manipulation of the blood in 
anyway is inherently dangerous and can result in death. The 
authors strongly discourage anyone from undertaking any 
form of blood manipulation except under the close super-
vision of a trained medical specialist as part of a research 
trial or as a planned medical intervention for ill health.
The authors would also advocate that anyone manipulat-
ing their blood within the rules of the World Anti-Doping 
Authorities (WADA) such as by altitude training or artificial 
hypobaric environment usage do so under the close super-
vision of a medical professional experienced in the manipu-
lation of haemoglobin. https://www.wada-ama.org/.
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